팔로우할 아티스트
주간 인기 트랙
활동을 찾을 수 없습니다.
- 남성
- 소셜 링크
- 그는 ~였다
-
Studies that randomized overweight or obese men to diet and exercise programs had significantly greater increases in total testosterone levels than men who underwent calorie reduction or exercise programs alone.378, 379 It is also postulated that men who engage in quantitatively more exercise have the greatest increases in serum testosterone from baseline.378 Prostate cancer patients on testosterone therapy should have their PSA levels monitored on the same schedule as men without testosterone deficiency; however, clinicians may choose to increase the frequency of testing. Given the reproductive profile of the study population, the spermatogenesis results might not be generalizable to patients with testosterone deficiency.332A study of 66 males who presented with infertility while on exogenous testosterone therapy revealed several interesting findings.333 The authors used a total motile sperm count (TMSC) of 5 million as the benchmark for spermatogenesis recovery. The main purpose of testosterone therapy is to return patients to normal physiological testosterone levels and provide relief of symptoms or signs.
The most common adverse effect of AndroGel® 1.62% was increased PSA level (29). It should be noted that application sites for 1.62% gel only include the shoulders and upper arms, and not the abdomen. The recommended starting dose of AndroGel® 1.62% is 40.5 mg applied topically once daily in the morning.
However, as the testosterone literature uses absolute values to define low testosterone, the absolute value is ultimately the most important factor to determine whether patients may expect to achieve benefits with testosterone therapy. As an example, a total testosterone value of 250 ng/dL may be considered low based on the current guideline but be marked within the normal range by the laboratory. Well-established reference ranges constitute the essential basis for identifying whether the circulating levels of a particular analyte, testosterone in this case, are normal or low. A review by Millar et al.4 searched MEDLINE and Embase databases from January 1966 to July 2014 for studies that compared clinical indication of low testosterone along with a measurement of serum testosterone in men. Evidence strength refers to the body of evidence available for a particular question and includes not only individual study quality but consideration of study design, consistency of findings across studies, adequacy of sample sizes, and generalizability of samples, settings, and treatments for the purposes of the guideline. Testosterone therapy refers to all forms of treatment that are aimed at increasing serum testosterone, including exogenous testosterone as well as alternative strategies, such as selective estrogen receptor modulators (SERMs), human chorionic gonadotropin (hCG) or aromatase inhibitors (AIs). Clinicians should discuss the risk of transference with patients using testosterone gels/creams.
The treatment and placebo arms did not differ at baseline in terms of age (62.9 years versus 64.4 years, respectively), total testosterone level (320 ng/dL versus 344 ng/dL, respectively), or PSA measurements (1.3 ng/mL in both arms). Overall, seven studies reported no benefits on QoL in men using testosterone therapy compared to placebo,199, 205, 212, 225, 226, 230, 303, 318 while five studies demonstrated improvements.203, 317, 319, 328, 329 The impact of testosterone therapy on QoL in men with testosterone deficiency is challenging to quantify due to variable study methodology and inherent limitations with standardized questionnaires.
The importance of diurnal variation of endogenous T is not fully understood, but there may be additional factors (eg, sleep quality and duration) that may influence endogenous T levels.96 However, further clarification is needed for the association between the circadian timing of sleep loss and its effect on T levels. This amplitude in daily endogenous T variation decreases with age, with a morning‐to‐afternoon difference of only 10% in 70‐year‐old men.90 The morning‐to‐afternoon total T ratios in young and older men were approximately 1.3 and 1.1, respectively, similar to what was observed in the Bremner study. As oral TU is given twice daily, there were 2 serum T peaks between 20.8 and 24.3 nmol/L (600 and 700 ng/dl) approximately 4 h after administration, 2 sub‐therapeutic troughs (
SQ testosterone pellets were initially developed and FDA approved in 1972 and were reformulated in the USA in 2008. Patients should be monitored for 30 minutes in a healthcare setting after injection to monitor for POME or anaphylactic-type symptoms. Mild level adverse events specific to SQ pellet insertion includes polycythemia (48-50%), ecchymosis (32-36%), tenderness (20-32%), pain (28-29%), and swelling (16-18%), all of which resolve by 4 months post-insertion.446 Moderate level adverse events were less common (e.g., pain 3%, erythema 3%, ecchymoses 7%) and improved within 1 week. These recommendations, however, are not based on current testosterone pellet formulations and contrast with pharmacokinetic data available. The unique pharmacokinetic profile of testosterone pellets is due to their crystalline structure, which dissolves slowly in SQ spaces.
Hyperprolactinemia is an uncommon condition172, 173 but it is a well-established cause of secondary (central) testosterone deficiency and can lead to infertility, decreased libido, sexual dysfunction, and gynecomastia. A low or low/normal LH level points to a secondary (central) hypothalamic-pituitary defect, (hypogonadotropic hypogonadism), while an elevated LH level indicates a primary testicular defect (hypergonadotropic hypogonadism).168 In men with hypogonadotropic hypogonadism, the yield from adjunctive tests (e.g., prolactin measurement, pituitary imaging, iron studies) is increased. LH, which is routinely measured by immunoassay, may help to establish the etiology of testosterone deficiency and can be an important factor in determining if adjunctive tests should be ordered (Appendix C - refer to the Appendix C section in the left menu). Their role in diagnosing testosterone deficiency is unclear, and they should not be used at the expense of a full patient evaluation, including laboratory testosterone measurement. Depending upon the radiation dose, delivery modality, and underlying tumor type, LH deficiency rates in patients whose pituitary gland has been exposed to radiation is 10-96%.160
As the buccal system hydrates, it slowly forms a gel to allow sustained and controlled‐release of T over 12 h through the buccal mucosa. A testosterone buccal system (TBS) was approved by the FDA in June 2003 (STRIANT®, Endo Pharmaceuticals).82 Each TBS contains 30 mg T and is designed as a tablet‐like mucoadhesive system applied to the gum region twice daily. At day 90, the Cmax and Cmin were 32.4 nmol/L (934.9 ng/dl) and 7.0 nmol/L (200.9 ng/dl), respectively, with a peak‐to‐trough ratio of 4.7. The efficacy and safety of the 60 mg/day 2% topical T solution were evaluated in an open‐label trial enrolling 155 men with TD. The FDA originally approved ANDRODERM®,51 a non‐scrotal transdermal T patch, in 1995, with the 2.5 mg/day and 5.0 mg/day systems.
Three patients developed erythrocytosis that resulted in their discontinuation from the study (29). Four participants reported small, painless nodules that resolved within 2 days, while 2 participants developed urticaria at the injection site within a few hours that persisted for up to 3 days. Local and systemic adverse events during subcutaneous administration of testosterone esters (number of events in parenthesis) Table 3 summarizes the local and systemic adverse effects reported by studies that administered testosterone esters via SC. In addition, there is no risk of sciatic injury, administration can be accomplished using smaller needles, and the pain evoked during SC administration is usually lower. The main benefit of using the SC route for administration of testosterone esters over the traditional IM route is the ease of self-administration. Mean A, 5-dihydrotestosterone (DHT) and B, estradiol (E2) concentrations on weekly subcutaneous (SC) injections of 75 mg testosterone enanthate. - http://118.195.135.194:3000/gonzalonqn8513
